Achillion Announces Upcoming Oral Presentation and Nomination of ACH-4471 at #ASH2015

Achillion Pharmaceuticals, Inc. ACHN announced Saturday, that an upcoming oral presentation discussing the Company's novel small molecule factor D inhibitors will take place on Sunday, December 6, 2015 during the 57th Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL, December 5 – 8. Achillion also announced today the nomination of its first orally bioavailable, highly potent and specific factor D inhibitor, ACH-4471, which is expected to enter clinical development during the first quarter of 2016. "We believe our molecular level understanding of factor D has enabled us to develop exquisitely targeted inhibitors that can potentially provide highly See full press release